Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label long-term safety study of brivaracetam as adjunctive therapy in pediatric epilepsy
2020-003664-29Phase 3Completed
- Sponsor
- UCB
- Start
- Nov 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of brivaracetam in epilepsy, sponsored by UCB. Primary endpoint: Incidence of treatment-emergent adverse events. Started Nov 2020; status: completed.
02
Drugs
brivaracetam
03
Conditions
epilepsy
Beyond the preview
Go deeper on 2020-003664-29.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-003664-29.